Michael D George1,2, Brian C Sauer3,4, Chia-Chen Teng3,4, Grant W Cannon3,4, Bryant R England3,4, Gail S Kerr3,4, Ted R Mikuls3,4, Joshua F Baker3,4. 1. From the Philadelphia Veterans Affairs (VA) Medical Center and University of Pennsylvania, Philadelphia, Pennsylvania; Salt Lake City VA Medical Center and University of Utah, Salt Lake City, Utah; VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center (UNMC), Omaha, Nebraska; DC VA Medical Center, Georgetown and Howard University, Washington, D.C., USA. michael.george@uphs.upenn.edu. 2. M.D. George, MD, MSCE, University of Pennsylvania, VA Medical Center; B.C. Sauer, PhD, VA Medical Center, University of Utah; C.C. Teng, MS, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center; G.W. Cannon, MD, VA Medical Center, University of Utah; B.R. England, MD, VA Medical Center, University of Nebraska Medical Center; G.S. Kerr, MD, VA Medical Center, Georgetown and Howard Universities; T.R. Mikuls, MD, MSPH, VA Medical Center, University of Nebraska Medical Center; J.F. Baker, MD, MSCE, VA Medical Center, University of Pennsylvania. michael.george@uphs.upenn.edu. 3. From the Philadelphia Veterans Affairs (VA) Medical Center and University of Pennsylvania, Philadelphia, Pennsylvania; Salt Lake City VA Medical Center and University of Utah, Salt Lake City, Utah; VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center (UNMC), Omaha, Nebraska; DC VA Medical Center, Georgetown and Howard University, Washington, D.C., USA. 4. M.D. George, MD, MSCE, University of Pennsylvania, VA Medical Center; B.C. Sauer, PhD, VA Medical Center, University of Utah; C.C. Teng, MS, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center; G.W. Cannon, MD, VA Medical Center, University of Utah; B.R. England, MD, VA Medical Center, University of Nebraska Medical Center; G.S. Kerr, MD, VA Medical Center, Georgetown and Howard Universities; T.R. Mikuls, MD, MSPH, VA Medical Center, University of Nebraska Medical Center; J.F. Baker, MD, MSCE, VA Medical Center, University of Pennsylvania.
Abstract
OBJECTIVE: Biologic therapies can improve disease control for patients with rheumatoid arthritis (RA) but may be both overused and underused. We aimed to identify predictors of greater use of biologic therapies and to identify factors associated with persistent glucocorticoid use. METHODS: Using national US Veteran's Affairs databases 2005-2016, we identified patients with RA receiving a first-ever prescription of methotrexate (MTX), requiring ≥ 6 months of baseline data. We evaluated predictors of biologic therapy initiation within 2 years of starting MTX and factors associated with baseline and persistent glucocorticoid use at 6-12 months using multivariable models. RESULTS: Among 17,415 patients starting MTX, 3263 patients received biologic therapy within 2 years (20.6% 2-yr incidence). In adjusted analyses, biologic use was substantially lower in older patients [e.g., aHR 0.20 (95% CI 0.16, 0.26) for patients ≥ 80 vs < 50] and patients with more comorbidities [aHR 0.79 (95% CI 0.72, 0.87) for Charlson score ≥ 3 vs < 3]. Patients with heart failure [aHR 0.68 (95% CI 0.54, 0.84)], cancer [aHR 0.78 (95% CI 0.66, 0.92)], or who were nonwhite [aHR 0.79 (95% CI 0.72, 0.87)] were also less likely to receive a biologic. In contrast, baseline and persistent glucocorticoid use was similar across age groups and more common in patients with greater comorbidity. CONCLUSION: Biologic therapy is initiated less frequently in patients with RA who are older, have more comorbidities, and who are nonwhite. While biologics may be avoided in older and sicker patients because of safety concerns, glucocorticoid use is similar regardless of age and is more frequent in patients with comorbidities, with implications for patient outcomes.
OBJECTIVE: Biologic therapies can improve disease control for patients with rheumatoid arthritis (RA) but may be both overused and underused. We aimed to identify predictors of greater use of biologic therapies and to identify factors associated with persistent glucocorticoid use. METHODS: Using national US Veteran's Affairs databases 2005-2016, we identified patients with RA receiving a first-ever prescription of methotrexate (MTX), requiring ≥ 6 months of baseline data. We evaluated predictors of biologic therapy initiation within 2 years of starting MTX and factors associated with baseline and persistent glucocorticoid use at 6-12 months using multivariable models. RESULTS: Among 17,415 patients starting MTX, 3263 patients received biologic therapy within 2 years (20.6% 2-yr incidence). In adjusted analyses, biologic use was substantially lower in older patients [e.g., aHR 0.20 (95% CI 0.16, 0.26) for patients ≥ 80 vs < 50] and patients with more comorbidities [aHR 0.79 (95% CI 0.72, 0.87) for Charlson score ≥ 3 vs < 3]. Patients with heart failure [aHR 0.68 (95% CI 0.54, 0.84)], cancer [aHR 0.78 (95% CI 0.66, 0.92)], or who were nonwhite [aHR 0.79 (95% CI 0.72, 0.87)] were also less likely to receive a biologic. In contrast, baseline and persistent glucocorticoid use was similar across age groups and more common in patients with greater comorbidity. CONCLUSION: Biologic therapy is initiated less frequently in patients with RA who are older, have more comorbidities, and who are nonwhite. While biologics may be avoided in older and sicker patients because of safety concerns, glucocorticoid use is similar regardless of age and is more frequent in patients with comorbidities, with implications for patient outcomes.
Entities:
Keywords:
BIOLOGICAL THERAPY; COMORBIDITY; GLUCOCORTICOIDS; PHYSICIANS’ PRACTICE PATTERNS; RHEUMATOID ARTHRITIS
Authors: Christina A Spivey; Jenny Griffith; Cameron Kaplan; Arnold Postlethwaite; Arijit Ganguli; Junling Wang Journal: Rheumatol Ther Date: 2017-12-04
Authors: Grant W Cannon; Ted R Mikuls; Candace L Hayden; Jian Ying; Jeffrey R Curtis; Andreas M Reimold; Liron Caplan; Gail S Kerr; J Steuart Richards; Dannette S Johnson; Brian C Sauer Journal: Arthritis Care Res (Hoboken) Date: 2011-12 Impact factor: 4.794
Authors: Jeffrey R Curtis; Lang Chen; Leslie R Harrold; Pongthorn Narongroeknawin; George Reed; Daniel H Solomon Journal: Arthritis Care Res (Hoboken) Date: 2010-01-15 Impact factor: 4.794
Authors: Jasvinder A Singh; Kenneth G Saag; S Louis Bridges; Elie A Akl; Raveendhara R Bannuru; Matthew C Sullivan; Elizaveta Vaysbrot; Christine McNaughton; Mikala Osani; Robert H Shmerling; Jeffrey R Curtis; Daniel E Furst; Deborah Parks; Arthur Kavanaugh; James O'Dell; Charles King; Amye Leong; Eric L Matteson; John T Schousboe; Barbara Drevlow; Seth Ginsberg; James Grober; E William St Clair; Elizabeth Tindall; Amy S Miller; Timothy McAlindon Journal: Arthritis Rheumatol Date: 2015-11-06 Impact factor: 10.995
Authors: Seo Young Kim; Amber Servi; Jennifer M Polinski; Helen Mogun; Michael E Weinblatt; Jeffrey N Katz; Daniel H Solomon Journal: Arthritis Res Ther Date: 2011-02-23 Impact factor: 5.156
Authors: Brian C Sauer; Chia-Chen Teng; Derek Tang; Jianwei Leng; Jeffrey R Curtis; Ted R Mikuls; David J Harrison; Grant W Cannon Journal: Arthritis Care Res (Hoboken) Date: 2017-03 Impact factor: 4.794
Authors: Michael D George; Joshua F Baker; Beth Wallace; Lang Chen; Qufei Wu; Fenglong Xie; Huifeng Yun; Jeffrey R Curtis Journal: Arthritis Care Res (Hoboken) Date: 2021-10-07 Impact factor: 4.794
Authors: Michael D George; Joshua F Baker; Kevin Winthrop; Jesse Y Hsu; Qufei Wu; Lang Chen; Fenglong Xie; Huifeng Yun; Jeffrey R Curtis Journal: Ann Intern Med Date: 2020-09-22 Impact factor: 25.391
Authors: Michael D George; Joshua F Baker; Kevin L Winthrop; Seth D Goldstein; E Alemao; Lang Chen; Qufei Wu; Fenglong Xie; Jeffrey R Curtis Journal: Ann Rheum Dis Date: 2020-03-24 Impact factor: 19.103
Authors: Kathleen M Andersen; Orit Schieir; Marie-France Valois; Susan J Bartlett; Louis Bessette; Gilles Boire; Boulos Haraoui; Glen Hazlewood; Carol Hitchon; Edward C Keystone; Janet Pope; Diane Tin; J Carter Throne; Vivian P Bykerk Journal: ACR Open Rheumatol Date: 2021-10-28
Authors: Beth I Wallace; Meriah N Moore; Andrew C Heisler; Lutfiyya N Muhammad; Jing Song; Daniel J Clauw; Clifton O Bingham; Marcy B Bolster; Wendy Marder; Tuhina Neogi; Alyssa Wohlfahrt; Dorothy D Dunlop; Yvonne C Lee Journal: Rheumatology (Oxford) Date: 2022-04-11 Impact factor: 7.046